Abstract Mutations in postsynaptic scaffolding genes contribute to autism, thus suggesting a role in pathological processes in neurodevelopment. Recently, two de novo mutations in SHANK3 were described in schizophrenia patients. In most cases, abnormal SHANK3 genotype was also accompanied by cognitive disruptions. The present study queries whether common SHANK variants may also contribute to neuropsychological dysfunctions in schizophrenia. We genotyped five common coding or promoter variants located in SHANK1, SHANK2 and SHANK3. A comprehensive test battery was used to assess neuropsychological functions in 199 schizophrenia patients and 206 healthy control subjects. In addition, an independent sample of 77 subjects at risk for psychosis was analyzed for replication of significant findings. We found the T allele of the SHANK1 promoter variant rs3810280 to lead to significantly impaired auditory working memory as assessed with digit span (12.5 ± 3.6 vs. 14.8 ± 4.1, P \ .001) in schizophrenia cases, applying strict Bonferroni correction for multiple testing. This finding was replicated for forward digit span in the at-risk sample (7.1 ± 2.0 vs. 8.3 ± 2.0, P = .044). Previously, altered memory functions and reduced dendritic spines and postsynaptic density of excitatory synapses were reported in SHANK1 knock-out mice. Moreover, the atypical neuroleptic clozapine was found to increase SHANK1 density in rats. Our findings suggest a role of SHANK1 in working memory deficits in schizophrenia, which may arise from neurodevelopmental changes to prefrontal cortical areas.
Introduction
Most researchers consider schizophrenia a neurodevelopmental disorder, which is highly determined by genetic factors [29] . Several schizophrenia candidate genes have been identified with some of them being involved in neurodevelopmental processes and neural plasticity [3, 15, 30] . However, none of the investigated variants linked with schizophrenia did account for a substantial part of variance, thus underlining the complex and polygenic heredity of the disorder. Moreover, the exact functional role of putative risk genes remains largely unknown.
Recently, research on the genetic foundations of autism spectrum disorders (ASD) indicated a role of the SHANK genes as being relevant to neurodevelopmental disorders. These genes encode scaffolding proteins (SHANK proteins) involved in the construction of the postsynaptic density (PSD) and dendritic spines of excitatory synapses [5] . More precisely, SHANK proteins constitute master scaffolding proteins interconnecting proteins bound to neurotransmitter receptors or the cytoskeleton [39, 41] . The fundamental role of SHANK in the organization of the PSD is further highlighted by an increase in number and size of dendritic synapses due to SHANK expression [32] . With regard to psychopathology, several mutations of the SHANK genes have been linked with ASD. In addition, most published cases also exhibited speech difficulties, intellectual impairments or mental retardation [8, 13, 18, 26] . Recently, Gauthier and coworkers also presented data suggesting a role of SHANK in schizophrenia with two de novo mutations reported in SHANK3. One of these mutations was found in 3 siblings from one family, all affected with schizophrenia or schizoaffective disorder and presenting borderline mental retardation or mental retardation. The second mutation was identified in a woman with schizoaffective disorder, speech difficulties and poor intellectual abilities [17] . Investigating common variants of genes harboring disease-associated mutations is a promising approach to identify molecular etiological factors. This research strategy was successfully applied with regard to the transcription factor 4 gene (TCF4). Mutations of this gene were previously related to Pitt-Hopkins syndrome and mental retardation [23, 43] . Recently, a large genomewide association study reported an association of a TCF4 variant (rs9960767) and schizophrenia [37] . Moreover, we found significantly reduced prepulse inhibition, a major schizophrenia endophenotype, in carriers of the diseaserelated C allele of TCF4 in independent samples of schizophrenia patients and healthy volunteers [28] . Thus, common variants of genes of which mutations lead to severely disrupted neuronal functions may also elicit more subtle effects contributing to neurodevelopmental disorders such as schizophrenia.
Following the approach outlined above, we queried whether common polymorphisms located within the genes SHANK1, SHANK2 and SHANK3 are related to schizophrenia psychopathology. We screened NCBI for all common coding or promoter variants within these genes and identified 5 common variants. Based on prior findings, we assumed that these variants play a role in cognitive functioning, thus contributing to an underlying deficit of schizophrenia patients.
Materials and method

Participants
The schizophrenia sample consisted of n = 199 patients diagnosed according to the criteria of DSM-IV or ICD-10 [1, 40] . Patients were recruited at the Departments of Psychiatry of the Universities of Bonn, Cologne, Munich, and at the Central Institute of Mental Health in Mannheim. With the exception of 2 schizophrenia cases with an ancestry from Turkey and 3 cases with uncertain ancestry, all were of Central European ancestry. The schizophrenia patients were in most cases treated with antipsychotics but had to be on stable medication for participation in the neuropsychological testing. Subjects with any neurological disturbance were excluded prior to testing.
The healthy control group consisted of 206 subjects recruited from the general population of Bonn, Cologne, and Mannheim, Germany. The control subjects had to be free of lifetime psychiatric or neurological disorders and were all of German ancestry. With regard to the psychiatric family background of the healthy control subjects, all but 2 subjects had a negative family history for a psychotic disorder.
The sample of 77 subjects clinically at risk for developing a psychosis was recruited within the early detection and intervention program of the German Research Network on Schizophrenia described in detail elsewhere [6] . Briefly, an early or late at-risk state [34] was assumed following detailed criteria including alternatively the presence of a cognitive-perceptive basic symptom criterion (i.e. cognitive disturbances, acoustic and visual perception disturbances); a combination of a marked functional decline with either a 1st degree relative with a schizophrenia spectrum disorder or pre-or perinatal complications; attenuated positive symptoms (ideas of reference; odd beliefs or magical thinking; unusual perceptual experiences; odd thinking and speech; suspiciousness; or paranoid ideations) several times a week over a period of 3 months; or brief limited intermittent psychotic symptoms resolving without treatment within 7 days. For operationalization, the early recognition inventory (ERIraos) was employed [25, 33] . Subjects who previously received antipsychotic treatment or fulfilled criteria of present or past diagnosis of schizophrenic, schizophreniform, schizoaffective, delusional or bipolar disorder, present or past diagnosis of a brief psychotic disorder with a duration of more than 1 week or within the last 4 weeks regardless of its duration, organic brain disease or alcohol or drug dependence within the last 3 months were excluded from the at-risk study.
Procedures
All subjects gave their written informed consent prior to inclusion in the study. The study was approved by the local ethics committees. All subjects were tested with a neuropsychological test battery tapping several cognitive domains known to be affected in schizophrenia. The digit span test of the Wechsler Adult Intelligence Scale [WAIS-R, 38] was used to assess auditory working memory with total repeated number sequences as the dependent measure. To assess processing speed, we used the digit symbol coding test from the WAIS-R with total coded symbols as the dependent measure. Parts A and B of the trail-making test were employed to measure viso-motor speed [31] . Verbal speech production was measured by a lexical fluency task asking the probands to produce as many words with a given initial letter (S, A, B, N) within 1 min with total correct words as dependent variable. Vigilance was assessed by the Continuous Performance Test-Identical Pairs with the deprime score d' reflecting a sensitivity measure composed of hits and false alarms as dependent variable [10] . The Rey Auditory Verbal Learning Test (RAVLT) was employed to assess verbal memory with learned words in the first trial, total learning in trials 1-5, delayed recall and recognition as dependent variables [21] . All neuropsychological tests and the cognitive functions measured are outlined in Table 1 .
Genotyping
NCBI was screened for all common coding or promoter variants located in the SHANK1, SHANK2 and SHANK3 genes, and five identified polymorphisms were genotyped subsequently. DNA for SNP genotyping was isolated from EDTA anticoagulated blood using the QIAGEN protocol for Blood & Cell Culture DNA Maxi Kit (QIAGEN, Hilden, Germany). PCR was performed using 12.5 ng of DNA, the Taqman Ò Universal PCR MasterMix, No AmpErase Ò UNG and the Taqman Ò SNP genotyping assay for the SNP (all provided by Applied Biosystems, Foster City, CA, USA) according to the protocol for Taqman Ò SNP genotyping (Applied Biosystems). Each assay consisted of the unlabeled forward and reverse primers and the FAM and VIC dye-labeled MGB probes. Those assays are designed for allelic discrimination of specific SNPs. Both alleles were scored in a single well by measuring the fluorescence at the end of the PCR using a Tecan Ultra 384 reader (Tecan, Crailsheim, Germany). Excitation and emission wavelengths for the FAM-labeled probes were 485 and 535 nm and for the VIC-labeled probes 535 and 590 nm, respectively. Analyzed variants are described in Table 2 . Detailed genotype information of the schizophrenia patients, the at-risk cases and the healthy control cases is presented in Table 3 . In all samples, the TT genotype frequency of the rs3810280 variant was very low (n = 5 schizophrenia patients, n = 1 at-risk subjects, n = 4 in the healthy control group). Thus, T-allele carriers were combined and contrasted against the CC genotype in all subsequent analyses. In the at-risk cases, we also observed very low frequencies of the AA genotype of the rs3745521 (n = 2) and thus combined A-allele carriers of this variant.
Statistical analyses
The relationship of genetic variants and demographic characteristics was investigated using ANOVAs for continuous data and Pearson chi 2 -Test for categorical data. We used the FAMHAP program [7] to compute case-control comparisons with regard to genotype distributions. For the analyses of a potential genetic association with cognitive performance, we used analyses of variances applying a strict significance level set at P = .001 (two-tailed), thus controlling for multiple testing by the Bonferroni method (5 variants 9 10 test parameters). Separate analyses were conducted in the schizophrenia patients and the healthy control group. In a second step, we attempted to replicate significant findings in the sample of subjects at risk for psychosis.
Results
The sample characteristics and genotypes are provided in Table 3 . All common variants were in Hardy-Weinberg equilibrium in the schizophrenia patients and the healthy control subjects (P = ns) and were unrelated to disease status in the case-control comparisons (all P = ns). Clinical and demographic characteristics were unaffected by SHANK genotype in the schizophrenia, at-risk cases and healthy control subjects (P = ns), with the exception of the rs9616915, for which female schizophrenia cases were more likely to be heterozygote (65.9% vs. 34.1%) while male schizophrenia cases were predominantly homozygote (55% vs. 45%) [chi 2 (2) = 8.46, P = .015]. We therefore introduced gender as a second factor in the analysis of rs9616915.
When analyzing neuropsychological data in the schizophrenia patients, a significant effect of the SHANK1 promoter variant rs3810280 on digit span was found which remained significant after correction for multiple testing. Cases with either a CT or TT genotype repeated only 12.5 ± 3.6 number sequences on average compared to 14.8 ± 4.1 sequences in carriers of the CC genotype [F(1, 195) = 13.74, P \ .001, eta p 2 = .07] (Fig. 1) . Additional post hoc analyses indicated that both, forward and backward digit spans, contributed equally to this deficit with T-allele carriers achieving significantly lower scores . These results remained significant after exclusion of schizophrenia patients with a non-Central European or uncertain ancestry (n = 5) (total digit span P \ .001, forward digit span P \ .001, backward digit span P = .008). In contrast to the significant finding in the schizophrenia patients, no effect of the SHANK1 promoter variant rs3810280 on digit span (CC: mean = 15.3 ± 3.8 vs. CT/TT: mean = 15.7 ± 3.9, [F(1, 168) = .16, P = .692]) or on any other neuropsychological test parameter was found in the healthy control group after correction for multiple testing. Combining the schizophrenia patients and the healthy control subjects, we still found an effect for the SHANK1 promoter variant rs3810280 on working memory. Thus, subjects with the CC genotype recalled 15.1 ± 3.9 number sequences on average compared to only 14.1 ± 4.1 sequences in T-allele carries. However, this finding was only nominally significant owing to the null effect of the SHANK1 variant in the healthy controls [F(1, 369) = 4.78, P = .029]. For the remaining SHANK variants, no association with neuropsychological performance was found in the schizophrenia patients and the healthy control subjects applying strict Bonferroni correction (P = ns).
We therefore aimed to confirm our finding for rs3810280 in the at-risk cases. A significant replication was found for forward digit span. Thus, at-risk subjects with a T allele showed a worse performance with 7.1 ± 2.0 recalled sequences on average compared to 8.3 ± 2.0 lines in carriers of the CC genotype [F(1, 54) = 4.27, P = .044, uncorrected P-value].
Discussion This is to our knowledge the first study relating common variants of SHANK1, SHANK2, and SHANK3 to schizophrenia. The present work investigated 5 common coding or promoter variants and their effect on neurocognitive endophenotypes in a sample of schizophrenia patients, atrisk cases and healthy control subjects. The T allele of the promoter variant rs3810280 of the SHANK1 gene was significantly related to reduced auditory working memory capacity in schizophrenia patients, even after controlling for multiple testing. With regard to forward digit span, this finding was replicated in the sample of subjects clinically at risk for developing a psychosis, while no effect was found in the group of healthy volunteers.
Previously, several mutations were identified within the SHANK genes, which contribute to ASD. These mutations were also accompanied by severely disturbed mental abilities suggesting a role of SHANK on fundamental cognitive functions [8, 13, 18, 26] . With regard to schizophrenia, the chromosome 22q harboring the SHANK3 gene was previously related to the disorder by linkage analyses yielding significant loci at 22q13 and by a case report of a duplication on 22q in a girl with schizophrenia and borderline mental retardation [9, 14] . Direct evidence for a role of SHANK genes in the disorder was recently published by Gauthier et al.: They found two de novo mutations of SHANK3 in cases suffering from schizophrenia [17] . In one family, all of three affected brothers diagnosed with either schizoaffective disorder or schizophrenia but not their parents carried the same mutation suggesting germline mosaicism. The second mutation was found in a woman diagnosed with schizoaffective disorder, speech impairments and poor psycho-social functioning. Interestingly, all of the four cases with identified de novo mutations also showed mental retardation or borderline mental retardation, thus underlining the potential influence of SHANK genes on cognitive functioning [17] . SHANK1, which showed highly significant effects in our study, was previously not examined in schizophrenia patients. However, a study conducted by Hung and colleagues investigated SHANK1 knock-out mice to explore the effect of this gene on synaptic maturation and cognitive functioning [22] . In this study, SHANK1 knock-out mice showed impaired fear-related memory, enhanced spatial learning but impaired long-term retention of space. Moreover, SHANK1 deficiency led to reduced basal synaptic transmission primarily caused by a reduction in functional synapses. The authors suggest a role of SHANK1 in the maturation of small dendritic spines into larger, more stable spines, thus leading to cognitive alterations [22] . Indirect evidence of a role of SHANK1 density in the psychopathology of schizophrenia stems from a study conducted by Critchlow et al. [11] : After treatment with the atypical neuroleptic clozapine, significantly increased SHANK1 density in primary and secondary dendritic spines of rat hippocampal neurons was observed while the classical antipsychotic drug haloperidol, in contrast, induced a reduction in SHANK1 density. Although it is far too early to draw any firm conclusions from this preliminary finding, it may be suggestive of a loss of SHANK1 proteins in the neurodevelopment of schizophrenia, which can be reversed by treatment with atypical antipsychotics. Working memory is a highly replicable core feature of cognitive impairments in schizophrenia, which is found independently from presentation and task [12, 24] . As outlined by Silver et al. [35] , evidence suggests that deficits in higher neuropsychological functions in schizophrenia may be partly caused by deficient working memory. For instance, successful in-depth processing or goal-oriented behaviors necessarily require retention of stimuli beyond visual or auditory presentation. In this view, the ''patients' lower working memory capacity is rate limiting in performance of other cognitive operations'' [p. 1813, 35] . In line with this assumption, Gold et al. [19] reported that the number of completed categories in the Wisconsin Card Sorting Test (WCST) was highly predicted by letter-number sequencing (LNS), a measure of working memory. Moreover, after controlling for LNS performance, WCST differences between schizophrenia patients and healthy controls were eliminated. Additionally, working memory impairment cannot be regarded as an epiphenomenon of schizophrenia symptoms. We observed reduced working memory capacity also in cases clinically at risk for psychosis [16] , and metaanalyses replicated such deficits in unaffected first-degree relatives of schizophrenia patients [36] . Confirming the role of genetics in working memory dysfunction, it has been shown that verbal working memory declines with higher familial loading in schizophrenia patients [42] . Thus, working memory constitutes a highly suitable schizophrenia endophenotype for genetic study protocols [20] .
The theoretical model of working memory elaborated by Baddeley [2] assumes a central executive system, which accesses three slave systems, the episodic buffer, the visuospatial sketch pad and the phonological loop. The latter refers to a system which is activated for phonological processing and auditory rehearsal of a given input such as digits [2] . While the forward digit span only requires maintenance of digit sequences, subjects have to store and mentally manipulate sequences in the backward condition. In our study, forward and backward digit spans were equally affected by SHANK1. Lesion studies found disrupted rehearsal of acoustic stimuli in patients with nonfluent aphasia commonly arising from damage to Broca's area [27] . In line with this, neuroimaging studies linked the articulatory rehearsal to the ventrolateral prefrontal cortex (Broca's area, BA 44, 45), while the phonological processing occurs in the left posterior parietal cortex [4] . With regard to the known neurobiological substrates of digit encoding and the finding of comparable effects of SHANK1 on forward and backward digit spans, the reported results might be suggestive of a role of SHANK1 in lateral prefrontal functions.
Based on the previous findings, our main hypothesis was that common SHANK variants would contribute to differential neuropsychological functioning. Although further studies are needed to clarify whether SHANK variants constitute schizophrenia susceptibility genes, our findings argue for a role of SHANK1 in aberrant cognitive functions, which are considered a core feature of schizophrenia. This main finding is further encouraged by the partial replication of SHANK1-affected impairments of working memory in cases at risk for psychosis. However, we did not observe any alterations due to SHANK variants in the healthy control cases. Thus, we cannot completely rule out potential genegene interactions of SHANK1 and other genetic variants conferring a risk for schizophrenia.
In conclusion, the SHANK1 promoter variant rs3818280 was found to contribute to deficient working memory in schizophrenia. Previously, it was shown that SHANK1 density increased after administration of the atypical antipsychotic clozapine indicating a role of SHANK1 in treatment response [11] . As has been demonstrated by Hung and coworkers, alterations of the SHANK1 gene may lead to reduced synaptic transmission probably due to synaptic loss [22] . Considering the neurobiological foundations of working memory in relation to our findings, we therefore suggest that future research should examine the role of SHANK variants on prefrontal structure and activation to further elucidate the exact mechanisms of altered working memory in schizophrenia.
